Abeona Therapeutics Inc. – NASDAQ:ABEO
Abeona Therapeutics stock price today
$6.92
+1.29
+22.91%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Abeona Therapeutics stock price monthly change
+2.18%
month
Abeona Therapeutics stock price quarterly change
+2.18%
quarter
Abeona Therapeutics stock price yearly change
+9.96%
year
Abeona Therapeutics key metrics
Market Cap | 245.17M |
Enterprise value | 16.28M |
P/E | -0.53 |
EV/Sales | 5.90 |
EV/EBITDA | -0.25 |
Price/Sales | 8.28 |
Price/Book | 0.85 |
PEG ratio | N/A |
EPS | -3.21 |
Revenue | N/A |
EBITDA | -47.45M |
Income | -76.65M |
Revenue Q/Q | N/A |
Revenue Y/Y | 492.13% |
Profit margin | -2629.13% |
Oper. margin | -2880.94% |
Gross margin | 23.55% |
EBIT margin | -2880.94% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAbeona Therapeutics stock price history
Abeona Therapeutics stock forecast
Abeona Therapeutics financial statements
| Jun 2023 | 3.5M | -16.65M | -475.83% |
|---|---|---|---|
| Sep 2023 | 0 | -11.83M | |
| Dec 2023 | 2.82M | -16.59M | -587.5% |
| Mar 2024 | 0 | -31.57M |
| Dec 2023 | 2.82M | -16.59M | -587.5% |
|---|---|---|---|
| Mar 2024 | 0 | -31.57M | |
| Oct 2025 | 3.75M | -9.01M | -240.38% |
| Dec 2025 | 12.75M | -3.96M | -31.06% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 53550000 | 44.20M | 82.55% |
|---|---|---|---|
| Sep 2023 | 66087000 | 44.04M | 66.65% |
| Dec 2023 | 64001999 | 49.17M | 76.84% |
| Mar 2024 | 74828000 | 83.70M | 111.87% |
| Jun 2023 | -10.28M | 5.21M | 6.61M |
|---|---|---|---|
| Sep 2023 | -5.74M | -18.74M | 22.97M |
| Dec 2023 | -9.23M | 11.52M | 7.46M |
| Mar 2024 | -14.53M | -7.81M | 25.44M |
Abeona Therapeutics alternative data
| Aug 2023 | 57 |
|---|---|
| Sep 2023 | 57 |
| Oct 2023 | 57 |
| Nov 2023 | 57 |
| Dec 2023 | 57 |
| Jan 2024 | 57 |
| Feb 2024 | 57 |
| Mar 2024 | 84 |
| Apr 2024 | 84 |
| May 2024 | 84 |
| Jun 2024 | 84 |
| Jul 2024 | 84 |
Abeona Therapeutics other data
100.00%
0.00%
of ABEO is owned by hedge funds
19
-20
1.42M
-6.75M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 26000 | 34057 |
| Jan 2024 | 0 | 7084 |
| Feb 2024 | 20000 | 0 |
| Apr 2024 | 31758 | 0 |
| May 2024 | 2959475 | 0 |
| Jun 2024 | 0 | 51711 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ALVINO MARK director | Common Stock | 25,890 | $4.51 | $116,764 | ||
Sale | SILVERSTEIN CHRISTINE BERNI director | Common Stock | 25,821 | $4.51 | $116,453 | ||
Purchase | ALLAND LEILA director | Common Stock | 11,000 | $4.71 | $51,799 | ||
Purchase | ADAGE CAPITAL MANAGEMENT, L.P. 10 percent owner | Pre-funded Warrant (right to buy) | 2,948,475 | N/A | N/A | ||
Purchase | CHARLES FAITH L. director | Common Stock | 7,550 | $3.28 | $24,764 | ||
Purchase | SESHADRI VISHWAS director, officer: Chief Execut.. | Common Stock | 10,000 | $3.2 | $32,000 | ||
Purchase | O'MALLEY BRENDAN M. officer: SVP, General Counsel | Common stock | 8,600 | $3.24 | $27,864 | ||
Purchase | VAZZANO JOSEPH WALTER officer: Chief Fi.. | Common stock | 5,608 | $3.14 | $17,609 | ||
Purchase | SESHADRI VISHWAS director, officer: Chief Execut.. | Common Stock | 20,000 | $4.39 | $87,800 | ||
Sale | ALVINO MARK director | Common Stock | 7,084 | $5.11 | $36,199 |
| Quarter | Transcript |
|---|---|
| Q3 2023 16 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 24 May 2023 | Q1 2023 Earnings Call Transcript |
| Q1 2022 17 May 2022 | Q1 2022 Earnings Call Transcript |
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
-
What's the price of Abeona Therapeutics stock today?
One share of Abeona Therapeutics stock can currently be purchased for approximately $6.92.
-
When is Abeona Therapeutics's next earnings date?
Unfortunately, Abeona Therapeutics's (ABEO) next earnings date is currently unknown.
-
Does Abeona Therapeutics pay dividends?
No, Abeona Therapeutics does not pay dividends.
-
How much money does Abeona Therapeutics make?
Abeona Therapeutics has a market capitalization of 245.17M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 147.52% to 3.5M US dollars.
-
What is Abeona Therapeutics's stock symbol?
Abeona Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "ABEO".
-
What is Abeona Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Abeona Therapeutics?
Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Abeona Therapeutics's key executives?
Abeona Therapeutics's management team includes the following people:
- Mr. Edward G. Carr Senior Vice President, Chief Financial Officer & Chief Accounting Officer(age: 56, pay: $437,400)
-
How many employees does Abeona Therapeutics have?
As Jul 2024, Abeona Therapeutics employs 84 workers.
-
When Abeona Therapeutics went public?
Abeona Therapeutics Inc. is publicly traded company for more then 45 years since IPO on 19 Sep 1980.
-
What is Abeona Therapeutics's official website?
The official website for Abeona Therapeutics is abeonatherapeutics.com.
-
Where are Abeona Therapeutics's headquarters?
Abeona Therapeutics is headquartered at 1330 Avenue of the Americas, New York, NY.
-
How can i contact Abeona Therapeutics?
Abeona Therapeutics's mailing address is 1330 Avenue of the Americas, New York, NY and company can be reached via phone at +64 6 813 4701.
Abeona Therapeutics company profile:
Abeona Therapeutics Inc.
abeonatherapeutics.comExchange:
NASDAQ
Full time employees:
84
Industry:
Biotechnology
Sector:
Healthcare
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
1330 Avenue of the Americas
New York, NY 10019
New York, NY 10019
CIK: 0000318306
ISIN: US00289Y2063
CUSIP: 00289Y107
